<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00630331</url>
  </required_header>
  <id_info>
    <org_study_id>V58P13</org_study_id>
    <secondary_id>2007-002871-15</secondary_id>
    <secondary_id>11580</secondary_id>
    <nct_id>NCT00630331</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Two Influenza Vaccines and Placebo in Healthy Adult Subjects</brief_title>
  <official_title>A Phase III, Randomized, Observer-Blind, Placebo-Controlled, Multicenter Study to Assess Clinical Efficacy of a Cell-Derived Subunit Influenza Vaccine and an Egg-Derived Subunit Influenza Vaccine in the 2007-2008 Influenza Season in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The present study will evaluate clinical efficacy, safety, tolerability and immunogenicity of
      both Novartis Vaccines' cell-derived influenza vaccine and egg-derived influenza vaccine in
      healthy adults 18 to 49 years of age.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With Culture-Confirmed Influenza Illness Caused by Vaccine-like Strains</measure>
    <time_frame>6 Months</time_frame>
    <description>The vaccine efficacy of CCI and IVV vaccines was estimated relative to Placebo group as the number of subjects prevented against virus-confirmed symptomatic influenza illness caused by each of three vaccine-like virus strains.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Culture-confirmed Influenza Illness Caused by Non-Vaccine Like Strains</measure>
    <time_frame>6 Months</time_frame>
    <description>The vaccine efficacy of CCI and IVV vaccines was estimated relative to placebo group as the number of subjects prevented against virus-confirmed symptomatic influenza A or B illness caused by non-vaccine-like strains.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Influenza Caused by Vaccine-like and Non-vaccine-like Strains</measure>
    <time_frame>6 Months</time_frame>
    <description>The vaccine efficacy of CCI and IVV vaccines was estimated relative to placebo as the number of subjected prevented against virus-confirmed symptomatic influenza A or B illness caused by vaccine-like and non-vaccine-like strains.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influenza-Associated Days in Bed, All Subjects</measure>
    <time_frame>6 Months</time_frame>
    <description>The number of subjects in this analysis included all subjects in the per protocol efficacy population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influenza-Associated Days in Bed, Subset of Subjects With Virus-Confirmed- Influenza</measure>
    <time_frame>6 Months</time_frame>
    <description>The analysis was done among the subset of subjects in the per protocol efficacy population who had culture-confirmed influenza.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number Of Medical Visits (Inpatient and Outpatient) Due to Influenza Illness or Symptoms of Influenza, All Subjects</measure>
    <time_frame>6 Months</time_frame>
    <description>The number of subjects in this analysis included all subjects in the per protocol efficacy population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Medical Visits (Inpatient and Outpatient), Subset of Subjects With Virus-Confirmed-Influenza</measure>
    <time_frame>6 Months</time_frame>
    <description>The analysis was done among the subset of subjects in the per protocol efficacy population who had culture-confirmed influenza.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days of Usual Activity (i.e. Job, School,Household/Family/Community Activities) Lost Due to Influenza Disease, All Subjects</measure>
    <time_frame>6 Months</time_frame>
    <description>The number of subjects in this analysis included all subjects in the per protocol efficacy population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days of Usual Activity (i.e. Job, School,Household/Family/Community Activities) Lost, Subset of Subjects With Virus-Confirmed-Influenza</measure>
    <time_frame>6 Months</time_frame>
    <description>The analysis was done among the subset of subjects in the per protocol efficacy population who had culture-confirmed influenza.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects Who Achieved HI Titers ≥40 After One Vaccination of Either Cell-culture Derived or Egg-derived Influenza Vaccine or Placebo</measure>
    <time_frame>Before vaccination (day 1) and three weeks after vaccination (day 22)</time_frame>
    <description>Immunogenicity was measured as the percentage of subjects achieving HI titers ≥40 at baseline (day 1) and three weeks after (day 22) one vaccination of either cell-culture or egg-derived vaccine or placebo for each of the three influenza vaccine strains (A/H1N1, A/H3N2 and B), evaluated using hemagglutination inhibition (HI) egg-derived antigen assay. This criterion is met according to US (CBER) guideline if the lower limit of the two-sided 95% CI for the percentage of subjects achieving HI titers ≥40 is ≥70%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects Achieving Seroconversion After One Vaccination of Either Cell-culture Derived or Egg-derived Influenza Vaccine or Placebo</measure>
    <time_frame>Three weeks after vaccination (day 22)</time_frame>
    <description>As per the CBER guideline, seroconversion is defined as the percentage of subjects with a prevaccination HI titer &lt;10, a postvaccination titer ≥40; or in subjects with prevaccination HI titer ≥10, a ≥4-fold increase in postvaccination HI antibody titer. According to CBER criteria, the lower limit of the two-sided 95% CI for the percentage of subjects achieving seroconversion for HI antibody titer at day 22 met exceeded 40%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reported Solicited Local and Systemic Reactions up to 7 Days After Vaccination</measure>
    <time_frame>Up to 7 days post vaccination</time_frame>
    <description>The solicited local and systemic reactogenicity were collected up to 7 days after vaccination for all three vaccine groups.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">11404</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>CCI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received one dose of cell culture-derived influenza vaccine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IVV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received one dose of the trivalent egg-derived influenza vaccine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects received one dose of phosphate buffered solution (PBS).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cell culture-derived influenza vaccine</intervention_name>
    <description>One dose (0.5 mL) of cell culture-derived influenza vaccine, administered in the deltoid muscle.</description>
    <arm_group_label>CCI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Egg-derived influenza virus vaccine</intervention_name>
    <description>One dose (0.5 mL) of the trivalent egg-derived influenza virus vaccine, administered in the deltoid muscle.</description>
    <arm_group_label>IVV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One dose (0.5 mL) of phosphate buffered solution.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. subjects 18 to 49 years of age;

          2. in good health as determined by medical history and physical examination;

          3. able and willing to provide written informed consent prior to any study procedure;

          4. able to comply with all study procedures, including availability and willingness to be
             actively followed throughout the ensuing influenza season with weekly telephone calls
             and to comply with the need for prompt collection of nasal and throat specimens in the
             event of influenza symptoms.

        Exclusion Criteria:

          1. history of anaphylaxis or serious reaction after administration of any vaccine, or
             hypersensitivity to eggs, egg protein, chicken feathers, influenza viral protein,
             neomycin, kanamycin, or any other vaccine component, chemically related substance, or
             component of the potential packaging materials;

          2. any health condition for which the inactivated vaccine is recommended by the Advisory
             Committee on Immunization Practices (ACIP) including chronic diseases of the pulmonary
             or cardiovascular systems (including asthma), chronic metabolic diseases (including
             diabetes), renal dysfunction, hemoglobinopathies, immune deficiency disease (including
             HIV infection) or on-going immunosuppressive therapy;

          3. employment in professions prone to influenza transmission to or from high-risk
             populations (this exclusion specifically includes nurses, physicians, all other
             healthcare workers with direct patient contact; and police, fire, and rescue
             personnel); or living in the same household as an immunocompromised person;

          4. history of Guillain-Barré syndrome;

          5. bleeding diathesis;

          6. receipt of another investigational agent within 90 days prior to enrollment in the
             study or before completion of the safety follow-up period in another study, whichever
             is longer, and unwilling to refuse participation in another clinical study through the
             end of the study;

          7. receipt of another vaccine within 2 weeks (for inactivated vaccines) or 4 weeks (for
             live vaccines) prior to Visit 1;

          8. laboratory-confirmed influenza disease within 6 months prior to Visit 1;

          9. receipt of an influenza vaccine within 6 months prior to Visit 1 or plans to receive
             influenza vaccine outside of this study;

         10. experienced a temperature (≥100.0°F / ≥37.8°C) and/or any acute illness within 3 days
             prior to study vaccination;

         11. pregnant or breast-feeding female;

         12. if female of childbearing potential and sexually active, has not used any of the birth
             control methods detailed in the section entitled &quot;Females of Childbearing Potential&quot;
             for at least 2 months prior to study entry;

         13. if female of childbearing potential and sexually active, refusal to use a reliable
             contraceptive method as detailed in the section entitled &quot;Females of Childbearing
             Potential&quot; during the first 3 weeks after vaccination;

         14. research staff directly involved with the clinical study or family members or
             household members of research staff. Research staff are individuals with direct or
             indirect contact with study subjects, or study site personnel who have access to any
             study documents containing subject information. This would include receptionists,
             persons scheduling appointments or making screening calls, regulatory specialists,
             laboratory technicians, etc.;

         15. any condition which, in the opinion of the investigator, might interfere with the
             evaluation of the study objectives or with the safety of the study subject.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Vaccines</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site 14</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 15</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 17</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 13</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 2</name>
      <address>
        <city>Bardstown</city>
        <state>Kentucky</state>
        <zip>40004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 1</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 4</name>
      <address>
        <city>Edison</city>
        <state>New Jersey</state>
        <zip>08817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 10</name>
      <address>
        <city>Binghamton</city>
        <state>New York</state>
        <zip>13901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 5</name>
      <address>
        <city>Endwell</city>
        <state>New York</state>
        <zip>13760</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 16</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 11</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 12</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 9</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 8</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 7</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 3</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 6</name>
      <address>
        <city>Burke</city>
        <state>Virginia</state>
        <zip>22105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 25</name>
      <address>
        <city>Espoo</city>
        <zip>02100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 26</name>
      <address>
        <city>Helsinki</city>
        <zip>00100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 27</name>
      <address>
        <city>Helsinki</city>
        <zip>00930</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 33</name>
      <address>
        <city>Järvenpää</city>
        <zip>04400</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 35</name>
      <address>
        <city>Kokkola</city>
        <zip>67100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 34</name>
      <address>
        <city>Kotka</city>
        <zip>48600</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 30</name>
      <address>
        <city>Kuopio</city>
        <zip>70100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 22</name>
      <address>
        <city>Lahti</city>
        <zip>15140</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 31</name>
      <address>
        <city>Oulu</city>
        <zip>90100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 23</name>
      <address>
        <city>Pori</city>
        <zip>28120</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 32</name>
      <address>
        <city>Seinäjoki</city>
        <zip>60100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 21</name>
      <address>
        <city>Tampere</city>
        <zip>33100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 24</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 28</name>
      <address>
        <city>Vantaa</city>
        <zip>01300</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 29</name>
      <address>
        <city>Vantaa</city>
        <zip>01600</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 49</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-316</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 53</name>
      <address>
        <city>Gniewkowo</city>
        <zip>88-140</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 59</name>
      <address>
        <city>Katowice</city>
        <zip>40-084</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 63</name>
      <address>
        <city>Kielce</city>
        <zip>25-711</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 62</name>
      <address>
        <city>Końskie</city>
        <zip>26-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 57</name>
      <address>
        <city>Krakow</city>
        <zip>30-510</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 41</name>
      <address>
        <city>Kraków</city>
        <zip>30-969</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 43</name>
      <address>
        <city>Kraków</city>
        <zip>31-115</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 42</name>
      <address>
        <city>Kraków</city>
        <zip>31-503</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 50</name>
      <address>
        <city>Kraków</city>
        <zip>31-832</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 44</name>
      <address>
        <city>Lubartów</city>
        <zip>21 - 100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 45</name>
      <address>
        <city>Lublin</city>
        <zip>20-044</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 65</name>
      <address>
        <city>Oleśnica</city>
        <zip>56-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 47</name>
      <address>
        <city>Olsztyn</city>
        <zip>10-117</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 48</name>
      <address>
        <city>Olsztyn</city>
        <zip>10-295</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 46</name>
      <address>
        <city>Olsztyn</city>
        <zip>10-461</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 58</name>
      <address>
        <city>Radziszów</city>
        <zip>32-052</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 61</name>
      <address>
        <city>Ruda Śląska</city>
        <zip>41-703</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 60</name>
      <address>
        <city>Rzeszów</city>
        <zip>35-324</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 52</name>
      <address>
        <city>Warszawa</city>
        <zip>02-777</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 55</name>
      <address>
        <city>Wilkowice</city>
        <zip>43-365</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 64</name>
      <address>
        <city>Wrocław</city>
        <zip>51-312</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 54</name>
      <address>
        <city>Wąbrzeźno</city>
        <zip>87-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 51</name>
      <address>
        <city>Łodź</city>
        <zip>90-302</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Frey S, Vesikari T, Szymczakiewicz-Multanowska A, Lattanzi M, Izu A, Groth N, Holmes S. Clinical efficacy of cell culture–derived and egg‐derived inactivated subunit influenza vaccines in healthy adults. Clin Infect Dis. 2010 Nov 1;51(9):997-1004. doi: 10.1086/656578.</citation>
    <PMID>20868284</PMID>
  </results_reference>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2008</study_first_submitted>
  <study_first_submitted_qc>March 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2008</study_first_posted>
  <results_first_submitted>November 21, 2012</results_first_submitted>
  <results_first_submitted_qc>January 15, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 16, 2013</results_first_posted>
  <disposition_first_submitted>March 16, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>March 16, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">March 28, 2011</disposition_first_posted>
  <last_update_submitted>January 15, 2013</last_update_submitted>
  <last_update_submitted_qc>January 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>Flu</keyword>
  <keyword>Cell Culture-Derived</keyword>
  <keyword>Egg-Derived</keyword>
  <keyword>Healthy Adults</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Safety</keyword>
  <keyword>Immunogenicity</keyword>
  <keyword>Trivalent</keyword>
  <keyword>Inactivated</keyword>
  <keyword>Influenza-Like Illness</keyword>
  <keyword>Vaccination</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled at multiple centres in the US, Poland and Finland.</recruitment_details>
      <pre_assignment_details>All enrolled subjects were included in the trial.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>CCI Vaccine</title>
          <description>One dose of cell culture-derived influenza vaccine.</description>
        </group>
        <group group_id="P2">
          <title>IVV Vaccine</title>
          <description>One dose of the trivalent egg-derived influenza virus vaccine.</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>One dose of phosphate buffered solution (PBS).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3828"/>
                <participants group_id="P2" count="3676"/>
                <participants group_id="P3" count="3900"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3622"/>
                <participants group_id="P2" count="3510"/>
                <participants group_id="P3" count="3712"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="206"/>
                <participants group_id="P2" count="166"/>
                <participants group_id="P3" count="188"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="175"/>
                <participants group_id="P2" count="143"/>
                <participants group_id="P3" count="170"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inappropriate enrollment</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unable to classify</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CCI Vaccine</title>
          <description>One dose of cell culture-derived influenza vaccine.</description>
        </group>
        <group group_id="B2">
          <title>IVV Vaccine</title>
          <description>One dose of the trivalent egg-derived influenza virus vaccine.</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>One dose of phosphate buffered solution (PBS).</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3828"/>
            <count group_id="B2" value="3676"/>
            <count group_id="B3" value="3900"/>
            <count group_id="B4" value="11404"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.7" spread="10.1"/>
                    <measurement group_id="B2" value="33.0" spread="10.2"/>
                    <measurement group_id="B3" value="32.7" spread="10.2"/>
                    <measurement group_id="B4" value="32.8" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <units>Subjects</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2088"/>
                    <measurement group_id="B2" value="2026"/>
                    <measurement group_id="B3" value="2176"/>
                    <measurement group_id="B4" value="6290"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1740"/>
                    <measurement group_id="B2" value="1649"/>
                    <measurement group_id="B3" value="1722"/>
                    <measurement group_id="B4" value="5111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Available</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Culture-Confirmed Influenza Illness Caused by Vaccine-like Strains</title>
        <description>The vaccine efficacy of CCI and IVV vaccines was estimated relative to Placebo group as the number of subjects prevented against virus-confirmed symptomatic influenza illness caused by each of three vaccine-like virus strains.</description>
        <time_frame>6 Months</time_frame>
        <population>Analysis was performed on per protocol (PP) efficacy population i.e. the subjects in the exposed efficacy population who correctly received the vaccine and provided evaluable swab samples at the relevant time points.</population>
        <group_list>
          <group group_id="O1">
            <title>CCI Vaccine</title>
            <description>One dose of cell culture-derived influenza vaccine.</description>
          </group>
          <group group_id="O2">
            <title>IVV Vaccine</title>
            <description>One dose of the trivalent egg-derived influenza virus vaccine.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>One dose of phosphate buffered solution (PBS).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Culture-Confirmed Influenza Illness Caused by Vaccine-like Strains</title>
          <description>The vaccine efficacy of CCI and IVV vaccines was estimated relative to Placebo group as the number of subjects prevented against virus-confirmed symptomatic influenza illness caused by each of three vaccine-like virus strains.</description>
          <population>Analysis was performed on per protocol (PP) efficacy population i.e. the subjects in the exposed efficacy population who correctly received the vaccine and provided evaluable swab samples at the relevant time points.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3776"/>
                <count group_id="O2" value="3638"/>
                <count group_id="O3" value="3843"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin/67/2005 (H3N2)-like</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Solomon Islands/3/2006 (H1N1)-like</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia/2506/2004-like</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Vaccine efficacy (VE) of CCI vaccine vs. Placebo (Overall)
Simultaneous one-sided 97.5% confidence interval (CI) for the VE of CCI vaccine relative to Placebo was based on the Sidak-corrected score CIs for the two relative risks.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Adjusted p-values are from score statistic with Sidak correction testing the null hypothesis that the VE of CCI vs. placebo is &lt;= 40% (the relative risk, &gt;= 0.60). If adjusted p-value is &lt;0.025, then the comparison is statistically significant.</p_value_desc>
            <method>Sidak-corrected score CI</method>
            <param_type>Vaccine Efficacy</param_type>
            <param_value>83.8</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>61.0</ci_lower_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Vaccine efficacy (VE) of CCI vaccine vs. Placebo for A/H1N1 strain
Simultaneous one-sided 97.5% confidence interval (CI) for the VE of CCI vaccine relative to Placebo was based on the Sidak-corrected score CIs for the two relative risks.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Adjusted p-values are from score statistic with Sidak correction testing the null hypothesis that the VE of CCI vs. placebo is &lt;= 40% (the relative risk, &gt;= 0.60). If adjusted p-value is &lt;0.025, then the comparison is statistically significant.</p_value_desc>
            <method>Sidak-corrected score CI</method>
            <param_type>Vaccine Efficacy</param_type>
            <param_value>88.2</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>67.4</ci_lower_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Vaccine efficacy (VE) of CCI vaccine vs. Placebo for A/H3N2 strain. Simultaneous one-sided 97.5% confidence interval (CI) for the VE of CCI vaccine relative to Placebo was based on the Sidak-corrected score CIs for the two relative risks.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.999</p_value>
            <p_value_desc>Adjusted p-values are from score statistic with Sidak correction testing the null hypothesis that the VE of CCI vs. placebo is &lt;= 40% (the relative risk, &gt;= 0.60). If adjusted p-value is &lt;0.025, then the comparison is statistically significant.</p_value_desc>
            <method>Sidak-corrected score CI</method>
            <method_desc>For strain A/H3N2, the vaccine efficacy of the CCI vaccine vs. placebo was not evaluable since no influenza case was observed in the placebo group.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Vaccine efficacy (VE) of CCI vaccine vs. Placebo for B strain
Simultaneous one-sided 97.5% confidence interval (CI) for the VE of CCI vaccine relative to Placebo was based on the Sidak-corrected score CIs for the two relative risks.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.394</p_value>
            <p_value_desc>Adjusted p-values are from score statistic with Sidak correction testing the null hypothesis that the VE of CCI vs. placebo is &lt;= 40% (the relative risk, &gt;= 0.60). If adjusted p-value is &lt;0.025, then the comparison is statistically significant.</p_value_desc>
            <method>Sidak-corrected score CI</method>
            <param_type>Vaccine Efficacy</param_type>
            <param_value>100</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>- 410</ci_lower_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Vaccine efficacy (VE) of IVV vaccine vs. Placebo (Overall)
Simultaneous one-sided 97.5% confidence interval (CI) for the VE of IVV vaccine relative to Placebo was based on the Sidak-corrected score CIs for the two relative risks.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <p_value_desc>Adjusted p-values are from score statistic with Sidak correction testing the null hypothesis that the VE of IVV vs. placebo is &lt;= 40% (the relative risk, &gt;= 0.60). If adjusted p-value is &lt;0.025, then the comparison is statistically significant.</p_value_desc>
            <method>Sidak-corrected score CI</method>
            <param_type>Vaccine Efficacy</param_type>
            <param_value>78.4</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>52.1</ci_lower_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Vaccine efficacy (VE) of IVV vaccine vs. Placebo for A/H1N1 strain
Simultaneous one-sided 97.5% confidence interval (CI) for the VE of IVV vaccine relative to Placebo was based on the Sidak-corrected score CIs for the two relative risks.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>Adjusted p-values are from score statistic with Sidak correction testing the null hypothesis that the VE of IVV vs. placebo is &lt;= 40% (the relative risk, &gt;= 0.60). If adjusted p-value is &lt;0.025, then the comparison is statistically significant.</p_value_desc>
            <method>Sidak-corrected score CI</method>
            <param_type>Vaccine Efficacy</param_type>
            <param_value>80.3</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>54.7</ci_lower_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Vaccine efficacy (VE) of IVV vaccine vs. Placebo for A/H3N2 strain. Simultaneous one-sided 97.5% confidence interval (CI) for the VE of IVV vaccine relative to Placebo was based on the Sidak-corrected score CIs for the two relative risks.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.992</p_value>
            <p_value_desc>Adjusted p-values are from score statistic with Sidak correction testing the null hypothesis that the VE of IVV vs. placebo is &lt;= 40% (the relative risk, &gt;= 0.60). If adjusted p-value is &lt;0.025, then the comparison is statistically significant.</p_value_desc>
            <method>Sidak-corrected score CI</method>
            <method_desc>For strain A/H3N2, the vaccine efficacy of the IVV vaccine vs. placebo was not evaluable since no influenza case was observed in the placebo group.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Vaccine efficacy (VE) of IVV vaccine vs. Placebo for B strain
Simultaneous one-sided 97.5% confidence interval (CI) for the VE of IVV vaccine relative to Placebo was based on the Sidak-corrected score CIs for the two relative risks.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.400</p_value>
            <p_value_desc>Adjusted p-values are from score statistic with Sidak correction testing the null hypothesis that the VE of IVV vs. placebo is &lt;= 40% (the relative risk, &gt;= 0.60). If adjusted p-value is &lt;0.025, then the comparison is statistically significant.</p_value_desc>
            <method>Sidak-corrected score CI</method>
            <param_type>Vaccine Efficacy</param_type>
            <param_value>100</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>- 429.4</ci_lower_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Culture-confirmed Influenza Illness Caused by Non-Vaccine Like Strains</title>
        <description>The vaccine efficacy of CCI and IVV vaccines was estimated relative to placebo group as the number of subjects prevented against virus-confirmed symptomatic influenza A or B illness caused by non-vaccine-like strains.</description>
        <time_frame>6 Months</time_frame>
        <population>Analysis was done on PP efficacy population.</population>
        <group_list>
          <group group_id="O1">
            <title>CCI Vaccine</title>
            <description>One dose of cell culture-derived influenza vaccine.</description>
          </group>
          <group group_id="O2">
            <title>IVV Vaccine</title>
            <description>One dose of the trivalent egg-derived influenza virus vaccine.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>One dose of phosphate buffered solution (PBS).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Culture-confirmed Influenza Illness Caused by Non-Vaccine Like Strains</title>
          <description>The vaccine efficacy of CCI and IVV vaccines was estimated relative to placebo group as the number of subjects prevented against virus-confirmed symptomatic influenza A or B illness caused by non-vaccine-like strains.</description>
          <population>Analysis was done on PP efficacy population.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3776"/>
                <count group_id="O2" value="3638"/>
                <count group_id="O3" value="3843"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Vaccine efficacy (VE) of CCI vaccine vs. Placebo (Overall)
Simultaneous one-sided 97.5% confidence interval (CI) for the VE of CCI vaccine relative to Placebo was based on the Sidak-corrected score CIs for the two relative risks.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.078</p_value>
            <p_value_desc>Adjusted p-values are from score statistic with Sidak correction testing the null hypothesis that the VE of CCI vs. placebo is &lt;= 40% (the relative risk, &gt;= 0.60). If adjusted p-value is &lt;0.025, then the comparison is statistically significant.</p_value_desc>
            <method>Sidak-corrected score CI</method>
            <param_type>Vaccine Efficacy</param_type>
            <param_value>58.7</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>33.5</ci_lower_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Vaccine efficacy (VE) of CCI vaccine vs. Placebo for A/H1N1 strain
Simultaneous one-sided 97.5% confidence interval (CI) for the VE of CCI vaccine relative to Placebo was based on the Sidak-corrected score CIs for the two relative risks.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.104</p_value>
            <p_value_desc>Adjusted p-values are from score statistic with Sidak correction testing the null hypothesis that the VE of CCI vs. placebo is &lt;= 40% (the relative risk, &gt;= 0.60). If adjusted p-value is &lt;0.025, then the comparison is statistically significant.</p_value_desc>
            <method>Sidak-corrected score CI</method>
            <param_type>Vaccine Efficacy</param_type>
            <param_value>87.3</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>4.6</ci_lower_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Vaccine efficacy (VE) of CCI vaccine vs. Placebo for A/H3N2 strain
Simultaneous one-sided 97.5% confidence interval (CI) for the VE of CCI vaccine relative to Placebo was based on the Sidak-corrected score CIs for the two relative risks.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.030</p_value>
            <p_value_desc>Adjusted p-values are from score statistic with Sidak correction testing the null hypothesis that the VE of CCI vs. placebo is &lt;= 40% (the relative risk, &gt;= 0.60). If adjusted p-value is &lt;0.025, then the comparison is statistically significant.</p_value_desc>
            <method>Sidak-corrected score CI</method>
            <param_type>Vaccine Efficacy</param_type>
            <param_value>100</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>36.3</ci_lower_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Vaccine efficacy (VE) of CCI vaccine vs. Placebo for B strain
Simultaneous one-sided 97.5% confidence interval (CI) for the VE of CCI vaccine relative to Placebo was based on the Sidak-corrected score CIs for the two relative risks.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.376</p_value>
            <p_value_desc>Adjusted p-values are from score statistic with Sidak correction testing the null hypothesis that the VE of CCI vs. placebo is &lt;= 40% (the relative risk, &gt;= 0.60). If adjusted p-value is &lt;0.025, then the comparison is statistically significant.</p_value_desc>
            <method>Sidak-corrected score CI</method>
            <param_type>Vaccine Efficacy</param_type>
            <param_value>50.0</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>17.5</ci_lower_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Vaccine efficacy (VE) of IVV vaccine vs. Placebo (Overall)
Simultaneous one-sided 97.5% confidence interval (CI) for the VE of IVV vaccine relative to Placebo was based on the Sidak-corrected score CIs for the two relative risks.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.085</p_value>
            <p_value_desc>Adjusted p-values are from score statistic with Sidak correction testing the null hypothesis that the VE of IVV vs. placebo is &lt;= 40% (the relative risk, &gt;= 0.60). If adjusted p-value is &lt;0.025, then the comparison is statistically significant.</p_value_desc>
            <method>Sidak-corrected score CI</method>
            <param_type>Vaccine Efficacy</param_type>
            <param_value>58.6</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>32.9</ci_lower_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Vaccine efficacy (VE) of IVV vaccine vs. Placebo for A/H1N1 strain
Simultaneous one-sided 97.5% confidence interval (CI) for the VE of IVV vaccine relative to Placebo was based on the Sidak-corrected score CIs for the two relative risks.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.033</p_value>
            <p_value_desc>Adjusted p-values are from score statistic with Sidak correction testing the null hypothesis that the VE of IVV vs. placebo is &lt;= 40% (the relative risk, &gt;= 0.60). If adjusted p-value is &lt;0.025, then the comparison is statistically significant.</p_value_desc>
            <method>Sidak-corrected score CI</method>
            <param_type>Vaccine Efficacy</param_type>
            <param_value>100</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>33.9</ci_lower_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Vaccine efficacy (VE) of IVV vaccine vs. Placebo for A/H3N2 strain
Simultaneous one-sided 97.5% confidence interval (CI) for the VE of IVV vaccine relative to Placebo was based on the Sidak-corrected score CIs for the two relative risks.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.265</p_value>
            <p_value_desc>Adjusted p-values are from score statistic with Sidak correction testing the null hypothesis that the VE of IVV vs. placebo is &lt;= 40% (the relative risk, &gt;= 0.60). If adjusted p-value is &lt;0.025, then the comparison is statistically significant.</p_value_desc>
            <method>Sidak-corrected score CI</method>
            <param_type>Vaccine Efficacy</param_type>
            <param_value>73.6</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>-30.0</ci_lower_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Vaccine efficacy (VE) of IVV vaccine vs. Placebo for B strain
Simultaneous one-sided 97.5% confidence interval (CI) for the VE of IVV vaccine relative to Placebo was based on the Sidak-corrected score CIs for the two relative risks.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.319</p_value>
            <p_value_desc>Adjusted p-values are from score statistic with Sidak correction testing the null hypothesis that the VE of IVV vs. placebo is &lt;= 40% (the relative risk, &gt;= 0.60). If adjusted p-value is &lt;0.025, then the comparison is statistically significant.</p_value_desc>
            <method>Sidak-corrected score CI</method>
            <param_type>Vaccine Efficacy</param_type>
            <param_value>51.7</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>19.4</ci_lower_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Influenza Caused by Vaccine-like and Non-vaccine-like Strains</title>
        <description>The vaccine efficacy of CCI and IVV vaccines was estimated relative to placebo as the number of subjected prevented against virus-confirmed symptomatic influenza A or B illness caused by vaccine-like and non-vaccine-like strains.</description>
        <time_frame>6 Months</time_frame>
        <population>Analysis was done on PP efficacy population.</population>
        <group_list>
          <group group_id="O1">
            <title>CCI Vaccine</title>
            <description>One dose of cell culture-derived influenza vaccine.</description>
          </group>
          <group group_id="O2">
            <title>IVV Vaccine</title>
            <description>One dose of the trivalent egg-derived influenza virus vaccine.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>One dose of phosphate buffered solution (PBS).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Influenza Caused by Vaccine-like and Non-vaccine-like Strains</title>
          <description>The vaccine efficacy of CCI and IVV vaccines was estimated relative to placebo as the number of subjected prevented against virus-confirmed symptomatic influenza A or B illness caused by vaccine-like and non-vaccine-like strains.</description>
          <population>Analysis was done on PP efficacy population.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3776"/>
                <count group_id="O2" value="3638"/>
                <count group_id="O3" value="3843"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Vaccine efficacy (VE) of CCI vaccine vs. Placebo (Overall)
Simultaneous one-sided 97.5% confidence interval (CI) for the VE of CCI vaccine relative to Placebo was based on the Sidak-corrected score CIs for the two relative risks.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Adjusted p-values are from score statistic with Sidak correction testing the null hypothesis that the VE of CCI vs. placebo is &lt;= 40% (the relative risk, &gt;= 0.60). If adjusted p-value is &lt;0.025, then the comparison is statistically significant.</p_value_desc>
            <method>Sidak-corrected score CI</method>
            <param_type>Vaccine Efficacy</param_type>
            <param_value>69.5</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>55.0</ci_lower_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Vaccine efficacy (VE) of CCI vaccine vs. Placebo for A/H1N1 strain
Simultaneous one-sided 97.5% confidence interval (CI) for the VE of CCI vaccine relative to Placebo was based on the Sidak-corrected score CIs for the two relative risks.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Adjusted p-values are from score statistic with Sidak correction testing the null hypothesis that the VE of CCI vs. placebo is &lt;= 40% (the relative risk, &gt;= 0.60). If adjusted p-value is &lt;0.025, then the comparison is statistically significant.</p_value_desc>
            <method>Sidak-corrected score CI</method>
            <param_type>Vaccine Efficacy</param_type>
            <param_value>89.3</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>73.0</ci_lower_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Vaccine efficacy (VE) of CCI vaccine vs. Placebo for A/H3N2 strain
Simultaneous one-sided 97.5% confidence interval (CI) for the VE of CCI vaccine relative to Placebo was based on the Sidak-corrected score CIs for the two relative risks.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.040</p_value>
            <p_value_desc>Adjusted p-values are from score statistic with Sidak correction testing the null hypothesis that the VE of CCI vs. placebo is &lt;= 40% (the relative risk, &gt;= 0.60). If adjusted p-value is &lt;0.025, then the comparison is statistically significant.</p_value_desc>
            <method>Sidak-corrected score CI</method>
            <param_type>Vaccine Efficacy</param_type>
            <param_value>75.6</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>35.1</ci_lower_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Vaccine efficacy (VE) of CCI vaccine vs. Placebo for B strain
Simultaneous one-sided 97.5% confidence interval (CI) for the VE of CCI vaccine relative to Placebo was based on the Sidak-corrected score CIs for the two relative risks.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.37</p_value>
            <p_value_desc>Adjusted p-values are from score statistic with Sidak correction testing the null hypothesis that the VE of CCI vs. placebo is &lt;= 40% (the relative risk, &gt;= 0.60). If adjusted p-value is &lt;0.025, then the comparison is statistically significant.</p_value_desc>
            <method>Sidak-corrected score CI</method>
            <param_type>Vaccine Efficacy</param_type>
            <param_value>49.9</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>18.2</ci_lower_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Vaccine efficacy (VE) of IVV vaccine vs. Placebo (Overall)
Simultaneous one-sided 97.5% confidence interval (CI) for the VE of IVV vaccine relative to Placebo was based on the Sidak-corrected score CIs for the two relative risks.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <p_value_desc>Adjusted p-values are from score statistic with Sidak correction testing the null hypothesis that the VE of IVV vs. placebo is &lt;= 40% (the relative risk, &gt;= 0.60). If adjusted p-value is &lt;0.025, then the comparison is statistically significant.</p_value_desc>
            <method>Sidak-corrected score CI</method>
            <param_type>Vaccine Efficacy</param_type>
            <param_value>63.0</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>46.7</ci_lower_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Vaccine efficacy (VE) of IVV vaccine vs. Placebo for A/H1N1 strain
Simultaneous one-sided 97.5% confidence interval (CI) for the VE of IVV vaccine relative to Placebo was based on the Sidak-corrected score CIs for the two relative risks.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Adjusted p-values are from score statistic with Sidak correction testing the null hypothesis that the VE of IVV vs. placebo is &lt;= 40% (the relative risk, &gt;= 0.60). If adjusted p-value is &lt;0.025, then the comparison is statistically significant.</p_value_desc>
            <method>Sidak-corrected score CI</method>
            <param_type>Vaccine Efficacy</param_type>
            <param_value>81.5</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>60.9</ci_lower_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Vaccine efficacy (VE) of IVV vaccine vs. Placebo for A/H3N2 strain
Simultaneous one-sided 97.5% confidence interval (CI) for the VE of IVV vaccine relative to Placebo was based on the Sidak-corrected score CIs for the two relative risks.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.53</p_value>
            <p_value_desc>Adjusted p-values are from score statistic with Sidak correction testing the null hypothesis that the VE of IVV vs. placebo is &lt;= 40% (the relative risk, &gt;= 0.60). If adjusted p-value is &lt;0.025, then the comparison is statistically significant.</p_value_desc>
            <method>Sidak-corrected score CI</method>
            <param_type>Vaccine Efficacy</param_type>
            <param_value>49.3</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>- 9.0</ci_lower_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Vaccine efficacy (VE) of IVV vaccine vs. Placebo for B strain
Simultaneous one-sided 97.5% confidence interval (CI) for the VE of IVV vaccine relative to Placebo was based on the Sidak-corrected score CIs for the two relative risks.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.26</p_value>
            <p_value_desc>Adjusted p-values are from score statistic with Sidak correction testing the null hypothesis that the VE of IVV vs. placebo is &lt;= 40% (the relative risk, &gt;= 0.60). If adjusted p-value is &lt;0.025, then the comparison is statistically significant.</p_value_desc>
            <method>Sidak-corrected score CI</method>
            <param_type>Vaccine Efficacy</param_type>
            <param_value>53.2</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>22.2</ci_lower_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Influenza-Associated Days in Bed, All Subjects</title>
        <description>The number of subjects in this analysis included all subjects in the per protocol efficacy population.</description>
        <time_frame>6 Months</time_frame>
        <population>Analysis was done on the PP efficacy population.</population>
        <group_list>
          <group group_id="O1">
            <title>CCI Vaccine</title>
            <description>One dose of cell culture-derived influenza vaccine.</description>
          </group>
          <group group_id="O2">
            <title>IVV Vaccine</title>
            <description>One dose of the trivalent egg-derived influenza virus vaccine.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>One dose of phosphate buffered solution (PBS).</description>
          </group>
        </group_list>
        <measure>
          <title>Influenza-Associated Days in Bed, All Subjects</title>
          <description>The number of subjects in this analysis included all subjects in the per protocol efficacy population.</description>
          <population>Analysis was done on the PP efficacy population.</population>
          <units>Number of Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3775"/>
                <count group_id="O2" value="3638"/>
                <count group_id="O3" value="3837"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.496"/>
                    <measurement group_id="O2" value="0.04" spread="0.404"/>
                    <measurement group_id="O3" value="0.12" spread="0.777"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Influenza-Associated Days in Bed, Subset of Subjects With Virus-Confirmed- Influenza</title>
        <description>The analysis was done among the subset of subjects in the per protocol efficacy population who had culture-confirmed influenza.</description>
        <time_frame>6 Months</time_frame>
        <population>Analysis was done on PP efficacy population.</population>
        <group_list>
          <group group_id="O1">
            <title>CCI Vaccine</title>
            <description>One dose of cell culture-derived influenza vaccine.</description>
          </group>
          <group group_id="O2">
            <title>IVV Vaccine</title>
            <description>One dose of the trivalent egg-derived influenza virus vaccine.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>One dose of phosphate buffered solution (PBS).</description>
          </group>
        </group_list>
        <measure>
          <title>Influenza-Associated Days in Bed, Subset of Subjects With Virus-Confirmed- Influenza</title>
          <description>The analysis was done among the subset of subjects in the per protocol efficacy population who had culture-confirmed influenza.</description>
          <population>Analysis was done on PP efficacy population.</population>
          <units>Number of Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="180"/>
                <count group_id="O2" value="230"/>
                <count group_id="O3" value="332"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="2.62"/>
                    <measurement group_id="O2" value="2.9" spread="1.98"/>
                    <measurement group_id="O3" value="3.4" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number Of Medical Visits (Inpatient and Outpatient) Due to Influenza Illness or Symptoms of Influenza, All Subjects</title>
        <description>The number of subjects in this analysis included all subjects in the per protocol efficacy population.</description>
        <time_frame>6 Months</time_frame>
        <population>Analysis was done of PP efficacy population.</population>
        <group_list>
          <group group_id="O1">
            <title>CCI Vaccine</title>
            <description>One dose of cell culture-derived influenza vaccine.</description>
          </group>
          <group group_id="O2">
            <title>IVV Vaccine</title>
            <description>One dose of the trivalent egg-derived influenza virus vaccine.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>One dose of phosphate buffered solution (PBS).</description>
          </group>
        </group_list>
        <measure>
          <title>Number Of Medical Visits (Inpatient and Outpatient) Due to Influenza Illness or Symptoms of Influenza, All Subjects</title>
          <description>The number of subjects in this analysis included all subjects in the per protocol efficacy population.</description>
          <population>Analysis was done of PP efficacy population.</population>
          <units>Number of Medical Visits</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3775"/>
                <count group_id="O2" value="3638"/>
                <count group_id="O3" value="3838"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.138"/>
                    <measurement group_id="O2" value="0.01" spread="0.134"/>
                    <measurement group_id="O3" value="0.03" spread="0.262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Medical Visits (Inpatient and Outpatient), Subset of Subjects With Virus-Confirmed-Influenza</title>
        <description>The analysis was done among the subset of subjects in the per protocol efficacy population who had culture-confirmed influenza.</description>
        <time_frame>6 Months</time_frame>
        <population>Analysis was done of PP efficacy population.</population>
        <group_list>
          <group group_id="O1">
            <title>CCI Vaccine</title>
            <description>One dose of cell culture-derived influenza vaccine.</description>
          </group>
          <group group_id="O2">
            <title>IVV Vaccine</title>
            <description>One dose of the trivalent egg-derived influenza virus vaccine.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>One dose of phosphate buffered solution (PBS).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Medical Visits (Inpatient and Outpatient), Subset of Subjects With Virus-Confirmed-Influenza</title>
          <description>The analysis was done among the subset of subjects in the per protocol efficacy population who had culture-confirmed influenza.</description>
          <population>Analysis was done of PP efficacy population.</population>
          <units>Number of Medical Visits</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="180"/>
                <count group_id="O2" value="230"/>
                <count group_id="O3" value="332"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="0.92"/>
                    <measurement group_id="O2" value="0.6" spread="1.0"/>
                    <measurement group_id="O3" value="0.8" spread="1.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days of Usual Activity (i.e. Job, School,Household/Family/Community Activities) Lost Due to Influenza Disease, All Subjects</title>
        <description>The number of subjects in this analysis included all subjects in the per protocol efficacy population.</description>
        <time_frame>6 Months</time_frame>
        <population>Analysis was done on PP efficacy population.</population>
        <group_list>
          <group group_id="O1">
            <title>CCI Vaccine</title>
            <description>One dose of cell culture-derived influenza vaccine.</description>
          </group>
          <group group_id="O2">
            <title>IVV Vaccine</title>
            <description>One dose of the trivalent egg-derived influenza virus vaccine.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>One dose of phosphate buffered solution (PBS).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days of Usual Activity (i.e. Job, School,Household/Family/Community Activities) Lost Due to Influenza Disease, All Subjects</title>
          <description>The number of subjects in this analysis included all subjects in the per protocol efficacy population.</description>
          <population>Analysis was done on PP efficacy population.</population>
          <units>Numebr of Days of Usual Activity Lost</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3775"/>
                <count group_id="O2" value="3638"/>
                <count group_id="O3" value="3837"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.635"/>
                    <measurement group_id="O2" value="0.05" spread="0.605"/>
                    <measurement group_id="O3" value="0.16" spread="1.006"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days of Usual Activity (i.e. Job, School,Household/Family/Community Activities) Lost, Subset of Subjects With Virus-Confirmed-Influenza</title>
        <description>The analysis was done among the subset of subjects in the per protocol efficacy population who had culture-confirmed influenza.</description>
        <time_frame>6 Months</time_frame>
        <population>Analysis was done on PP efficacy population.</population>
        <group_list>
          <group group_id="O1">
            <title>CCI Vaccine</title>
            <description>One dose of cell culture-derived influenza vaccine.</description>
          </group>
          <group group_id="O2">
            <title>IVV Vaccine</title>
            <description>One dose of the trivalent egg-derived influenza virus vaccine.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>One dose of phosphate buffered solution (PBS).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days of Usual Activity (i.e. Job, School,Household/Family/Community Activities) Lost, Subset of Subjects With Virus-Confirmed-Influenza</title>
          <description>The analysis was done among the subset of subjects in the per protocol efficacy population who had culture-confirmed influenza.</description>
          <population>Analysis was done on PP efficacy population.</population>
          <units>Numebr of Days of Usual Activity Lost</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="180"/>
                <count group_id="O2" value="230"/>
                <count group_id="O3" value="332"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" spread="3.41"/>
                    <measurement group_id="O2" value="4.0" spread="3.4"/>
                    <measurement group_id="O3" value="4.6" spread="3.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects Who Achieved HI Titers ≥40 After One Vaccination of Either Cell-culture Derived or Egg-derived Influenza Vaccine or Placebo</title>
        <description>Immunogenicity was measured as the percentage of subjects achieving HI titers ≥40 at baseline (day 1) and three weeks after (day 22) one vaccination of either cell-culture or egg-derived vaccine or placebo for each of the three influenza vaccine strains (A/H1N1, A/H3N2 and B), evaluated using hemagglutination inhibition (HI) egg-derived antigen assay. This criterion is met according to US (CBER) guideline if the lower limit of the two-sided 95% CI for the percentage of subjects achieving HI titers ≥40 is ≥70%.</description>
        <time_frame>Before vaccination (day 1) and three weeks after vaccination (day 22)</time_frame>
        <population>Analysis was done on a subset of subjects who constituted the PP immunogenicity population.</population>
        <group_list>
          <group group_id="O1">
            <title>CCI Vaccine</title>
            <description>One dose of cell culture-derived influenza vaccine.</description>
          </group>
          <group group_id="O2">
            <title>IVV Vaccine</title>
            <description>One dose of the trivalent egg-derived influenza virus vaccine.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>One dose of phosphate buffered solution (PBS).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects Who Achieved HI Titers ≥40 After One Vaccination of Either Cell-culture Derived or Egg-derived Influenza Vaccine or Placebo</title>
          <description>Immunogenicity was measured as the percentage of subjects achieving HI titers ≥40 at baseline (day 1) and three weeks after (day 22) one vaccination of either cell-culture or egg-derived vaccine or placebo for each of the three influenza vaccine strains (A/H1N1, A/H3N2 and B), evaluated using hemagglutination inhibition (HI) egg-derived antigen assay. This criterion is met according to US (CBER) guideline if the lower limit of the two-sided 95% CI for the percentage of subjects achieving HI titers ≥40 is ≥70%.</description>
          <population>Analysis was done on a subset of subjects who constituted the PP immunogenicity population.</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="228"/>
                <count group_id="O2" value="695"/>
                <count group_id="O3" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 - Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48" lower_limit="42" upper_limit="55"/>
                    <measurement group_id="O2" value="53" lower_limit="49" upper_limit="57"/>
                    <measurement group_id="O3" value="60" lower_limit="46" upper_limit="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1 - Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O2" value="98" lower_limit="97" upper_limit="99"/>
                    <measurement group_id="O3" value="60" lower_limit="46" upper_limit="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 - Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63" lower_limit="57" upper_limit="69"/>
                    <measurement group_id="O2" value="58" lower_limit="54" upper_limit="61"/>
                    <measurement group_id="O3" value="71" lower_limit="57" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 - Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O2" value="99" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O3" value="65" lower_limit="51" upper_limit="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B - Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25" lower_limit="20" upper_limit="31"/>
                    <measurement group_id="O2" value="23" lower_limit="20" upper_limit="27"/>
                    <measurement group_id="O3" value="22" lower_limit="12" upper_limit="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B - Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78" lower_limit="72" upper_limit="83"/>
                    <measurement group_id="O2" value="92" lower_limit="90" upper_limit="94"/>
                    <measurement group_id="O3" value="22" lower_limit="12" upper_limit="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects Achieving Seroconversion After One Vaccination of Either Cell-culture Derived or Egg-derived Influenza Vaccine or Placebo</title>
        <description>As per the CBER guideline, seroconversion is defined as the percentage of subjects with a prevaccination HI titer &lt;10, a postvaccination titer ≥40; or in subjects with prevaccination HI titer ≥10, a ≥4-fold increase in postvaccination HI antibody titer. According to CBER criteria, the lower limit of the two-sided 95% CI for the percentage of subjects achieving seroconversion for HI antibody titer at day 22 met exceeded 40%.</description>
        <time_frame>Three weeks after vaccination (day 22)</time_frame>
        <population>Analysis was done on a subset of subjects who constituted the PP immunogenicity population.</population>
        <group_list>
          <group group_id="O1">
            <title>CCI Vaccine</title>
            <description>One dose of cell culture-derived influenza vaccine.</description>
          </group>
          <group group_id="O2">
            <title>IVV Vaccine</title>
            <description>One dose of the trivalent egg-derived influenza virus vaccine.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>One dose of phosphate buffered solution (PBS).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects Achieving Seroconversion After One Vaccination of Either Cell-culture Derived or Egg-derived Influenza Vaccine or Placebo</title>
          <description>As per the CBER guideline, seroconversion is defined as the percentage of subjects with a prevaccination HI titer &lt;10, a postvaccination titer ≥40; or in subjects with prevaccination HI titer ≥10, a ≥4-fold increase in postvaccination HI antibody titer. According to CBER criteria, the lower limit of the two-sided 95% CI for the percentage of subjects achieving seroconversion for HI antibody titer at day 22 met exceeded 40%.</description>
          <population>Analysis was done on a subset of subjects who constituted the PP immunogenicity population.</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="228"/>
                <count group_id="O2" value="695"/>
                <count group_id="O3" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78" lower_limit="72" upper_limit="83"/>
                    <measurement group_id="O2" value="75" lower_limit="71" upper_limit="78"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59" lower_limit="53" upper_limit="66"/>
                    <measurement group_id="O2" value="68" lower_limit="64" upper_limit="71"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51" lower_limit="45" upper_limit="58"/>
                    <measurement group_id="O2" value="68" lower_limit="65" upper_limit="72"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reported Solicited Local and Systemic Reactions up to 7 Days After Vaccination</title>
        <description>The solicited local and systemic reactogenicity were collected up to 7 days after vaccination for all three vaccine groups.</description>
        <time_frame>Up to 7 days post vaccination</time_frame>
        <population>Analysis was done on Safety population i.e. all subjects in the exposed population who provide post vaccination safety data.</population>
        <group_list>
          <group group_id="O1">
            <title>CCI Vaccine</title>
            <description>One dose of cell culture-derived influenza vaccine.</description>
          </group>
          <group group_id="O2">
            <title>IVV Vaccine</title>
            <description>One dose of the trivalent egg-derived influenza virus vaccine.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>One dose of phosphate buffered solution (PBS).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reported Solicited Local and Systemic Reactions up to 7 Days After Vaccination</title>
          <description>The solicited local and systemic reactogenicity were collected up to 7 days after vaccination for all three vaccine groups.</description>
          <population>Analysis was done on Safety population i.e. all subjects in the exposed population who provide post vaccination safety data.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3813"/>
                <count group_id="O2" value="3669"/>
                <count group_id="O3" value="3894"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Injection site Pain (N=3813, 3668, 3894)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1158"/>
                    <measurement group_id="O2" value="893"/>
                    <measurement group_id="O3" value="375"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site Erythema (N=3813, 3668, 3894)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="510"/>
                    <measurement group_id="O2" value="492"/>
                    <measurement group_id="O3" value="391"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site Induration (N=3813,3668,3894)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="239"/>
                    <measurement group_id="O2" value="207"/>
                    <measurement group_id="O3" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site Ecchymosis (N=3813, 3668, 3894)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143"/>
                    <measurement group_id="O2" value="110"/>
                    <measurement group_id="O3" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site Swelling (N=3813, 3667, 3894)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218"/>
                    <measurement group_id="O2" value="181"/>
                    <measurement group_id="O3" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="210"/>
                    <measurement group_id="O2" value="211"/>
                    <measurement group_id="O3" value="223"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise (N=3813, 3669, 3893)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="290"/>
                    <measurement group_id="O2" value="259"/>
                    <measurement group_id="O3" value="237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia (N=3813, 3669, 3893)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="450"/>
                    <measurement group_id="O2" value="364"/>
                    <measurement group_id="O3" value="275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia (N=3813, 3669, 3893)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108"/>
                    <measurement group_id="O2" value="111"/>
                    <measurement group_id="O3" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (N=3813, 3669, 3893)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="564"/>
                    <measurement group_id="O2" value="551"/>
                    <measurement group_id="O3" value="592"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweating (N=3812, 3669, 3893)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124"/>
                    <measurement group_id="O2" value="122"/>
                    <measurement group_id="O3" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue (N=3812, 3669, 3893)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="390"/>
                    <measurement group_id="O2" value="404"/>
                    <measurement group_id="O3" value="384"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (&gt;= 38 C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oral Temp. (&lt; 38 C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3786"/>
                    <measurement group_id="O2" value="3648"/>
                    <measurement group_id="O3" value="3879"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stayed home due to Reactions (N=3781, 3651, 3867)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="62"/>
                    <measurement group_id="O3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Analgesic medicines used (N=3810, 3665, 3892)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="394"/>
                    <measurement group_id="O2" value="397"/>
                    <measurement group_id="O3" value="386"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious Adverse Events were collected throughout the study period (i.e., 6 months).</time_frame>
      <desc>The analysis was done on the safety population.</desc>
      <group_list>
        <group group_id="E1">
          <title>CCI Vaccine</title>
          <description>One dose of cell culture-derived influenza vaccine.</description>
        </group>
        <group group_id="E2">
          <title>IVV Vaccine</title>
          <description>One dose of the trivalent egg-derived influenza virus vaccine.</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>One dose of phosphate buffered solution (PBS).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="3813"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="3669"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="3894"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Failure Congestive</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Coronary Artery disease</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3894"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo Positional</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3813"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3669"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3894"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3894"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Mydriasis</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3894"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3813"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3669"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3813"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3669"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Anal Fistula</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3813"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3669"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Colitis Ischaemic</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3813"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3669"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Crohn's Disease</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal Reflux Disease</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Inguinal Hernia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3813"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3669"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Intestinal Obstructon</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3813"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3669"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Pancreatitis Acute</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Peritoneal Cyst</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Salivary Duct Inflammation</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Salivary Gland Calculus</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Small Intestinal Obstruction</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Vomiting in Pregnancy</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3813"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3669"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3894"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Non-Cardiac Chest Pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3894"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholangitis Sclerosing</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Cholecystitis Acute</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3813"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3669"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Hepatitis Acute</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3894"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute Sinusitis</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Acute Tonsillitis</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3813"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3669"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Breast Cellulitis</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Gastroenteritis Viral</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3813"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3669"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Lung Abscess</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Mastitis Bacterial</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Perirectal Abscess</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3813"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3669"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Peritonsillar Abscess</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3813"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3669"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3813"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3669"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Pyelonephritis Acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3813"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3669"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Wound Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3894"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Abdominal Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3813"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3669"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Alcohol Poisoning</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Ankle Fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Chest Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Extradural Haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Foot Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3813"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3669"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Joint Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3813"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3669"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Road Traffic Accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3813"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3669"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Skull Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Subdural Haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3813"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3669"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Tendon Rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Upper Limb Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3813"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3669"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3813"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3669"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3894"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3894"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Intervertebral Disc Protrusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="3894"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma of the Cervix</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Bone Neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Breast Cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Carcinoid Tumour</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Leiomyosarcoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Ovarian Cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3813"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3669"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3894"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral Haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3813"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3669"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Loss of Consciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Tethered Cord Syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3894"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion Spontaneous</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3813"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3669"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Delivery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Ectopic Pregnancy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3813"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3669"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3894"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Stress Disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3813"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3669"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Bipolar Disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Borderline Personality Disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Major Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3813"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3669"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Psychotic Disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3813"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3669"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3894"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder Prolapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3813"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3669"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Renal Failure Acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3894"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast Hyperplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Haemorrhagic Ovarian Cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3813"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3669"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Menometrorrhagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Pelvic Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Polycystic Ovaries</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Uterine Haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3894"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Nasal Septum Deviation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3813"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3669"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Tonsillar Hypertrophy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3894"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis Atopic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3894"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Homicide</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3813"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3669"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3894"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Aortic Valve Replacement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Appendicetomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Knee Operation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Medical Device Removal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3813"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3669"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Nasal Septal Operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3813"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3669"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Rhinoplasty</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3813"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3669"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Tendon Operation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3894"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3813"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3669"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Varicose Vein</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3813"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3669"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3894"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1949" subjects_at_risk="3813"/>
                <counts group_id="E2" subjects_affected="1703" subjects_at_risk="3669"/>
                <counts group_id="E3" subjects_affected="1387" subjects_at_risk="3894"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="212" subjects_at_risk="3813"/>
                <counts group_id="E2" subjects_affected="212" subjects_at_risk="3669"/>
                <counts group_id="E3" subjects_affected="225" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="390" subjects_at_risk="3813"/>
                <counts group_id="E2" subjects_affected="404" subjects_at_risk="3669"/>
                <counts group_id="E3" subjects_affected="386" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Injection Site Erythema</sub_title>
                <counts group_id="E1" subjects_affected="510" subjects_at_risk="3813"/>
                <counts group_id="E2" subjects_affected="492" subjects_at_risk="3669"/>
                <counts group_id="E3" subjects_affected="391" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Injection Site Induration</sub_title>
                <counts group_id="E1" subjects_affected="239" subjects_at_risk="3813"/>
                <counts group_id="E2" subjects_affected="207" subjects_at_risk="3669"/>
                <counts group_id="E3" subjects_affected="101" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Injection Site Pain</sub_title>
                <counts group_id="E1" subjects_affected="1158" subjects_at_risk="3813"/>
                <counts group_id="E2" subjects_affected="893" subjects_at_risk="3669"/>
                <counts group_id="E3" subjects_affected="375" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Injection Site Swelling</sub_title>
                <counts group_id="E1" subjects_affected="218" subjects_at_risk="3813"/>
                <counts group_id="E2" subjects_affected="181" subjects_at_risk="3669"/>
                <counts group_id="E3" subjects_affected="103" subjects_at_risk="3894"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="290" subjects_at_risk="3813"/>
                <counts group_id="E2" subjects_affected="260" subjects_at_risk="3669"/>
                <counts group_id="E3" subjects_affected="238" subjects_at_risk="3894"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="451" subjects_at_risk="3813"/>
                <counts group_id="E2" subjects_affected="369" subjects_at_risk="3669"/>
                <counts group_id="E3" subjects_affected="278" subjects_at_risk="3894"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="571" subjects_at_risk="3813"/>
                <counts group_id="E2" subjects_affected="554" subjects_at_risk="3669"/>
                <counts group_id="E3" subjects_affected="597" subjects_at_risk="3894"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Posting Director</name_or_title>
      <organization>Novartis Vaccines and Diagnostics</organization>
      <email>RegistryContactVaccinesUS@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

